Galapagos Proposes Name Change and Governance for Shareholder Vote
Galapagos NV has released its 2025 annual report and announced a joint ordinary general meeting and extraordinary general meeting scheduled for April 28, 2026. These shareholder meetings will decide on several board nominations and major strategic directions.
The ordinary general meeting (AGM) will be held on April 28, 2026, at 2:00 PM CET in Mechelen, Belgium. The agenda includes the appointment of Henry Gosebruch as executive director, the appointment of five independent non-executive directors (Jane Griffiths, Dawn Svoronos, Neil Johnston, Paulo Fontoura, and Gino Santini), and the appointment of Devang Bhuva as a non-executive director. The renewal of the auditor BDO Bedrijfsrevisoren is also on the agenda, along with the confirmation of their appointment for the sustainability assurance directive (CSRD).
Extraordinary General Meeting Agenda
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The extraordinary general meeting (EGM) will take place on April 28, 2026, at 3:00 PM CET, immediately following the AGM. It will address the proposed company name change to 'Lakefront Biotherapeutics', the authorization to repurchase up to 10% of the outstanding shares under certain limitations, and the renewal of the board's authorization to increase the share capital within the existing capital authorization framework.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 6.5M€
Net income: 14.5M€
Guidance from the release
Je suis particulièrement enthousiasmé par les progrès que nous réalisons.
Risks mentioned
Risque que la transaction avec Gilead ne soit pas finalisée dans les délais prévus.
Risques liés à la disponibilité des ressources financières pour des transactions stratégiques.
Incertitude liée aux coûts de restructuration d'environ 125 millions d'euros à 175 millions d'euros.
Opportunities identified
Opportunité de finaliser la collaboration avec Gilead au deuxième trimestre 2026.
Possibilité de dépenses jusqu'à 500 millions USD pour le développement commercial.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
